» Articles » PMID: 26878175

MLL-AF9- and HOXA9-mediated Acute Myeloid Leukemia Stem Cell Self-renewal Requires JMJD1C

Abstract

Self-renewal is a hallmark of both hematopoietic stem cells (HSCs) and leukemia stem cells (LSCs); therefore, the identification of mechanisms that are required for LSC, but not HSC, function could provide therapeutic opportunities that are more effective and less toxic than current treatments. Here, we employed an in vivo shRNA screen and identified jumonji domain-containing protein JMJD1C as an important driver of MLL-AF9 leukemia. Using a conditional mouse model, we showed that loss of JMJD1C substantially decreased LSC frequency and caused differentiation of MLL-AF9- and homeobox A9-driven (HOXA9-driven) leukemias. We determined that JMJD1C directly interacts with HOXA9 and modulates a HOXA9-controlled gene-expression program. In contrast, loss of JMJD1C led to only minor defects in blood homeostasis and modest effects on HSC self-renewal. Together, these data establish JMJD1C as an important mediator of MLL-AF9- and HOXA9-driven LSC function that is largely dispensable for HSC function.

Citing Articles

HOXA9 Regulome and Pharmacological Interventions in Leukemia.

Aryal S, Lu R Adv Exp Med Biol. 2024; 1459:405-430.

PMID: 39017854 DOI: 10.1007/978-3-031-62731-6_18.


Epigenetic roles of KDM3B and KDM3C in tumorigenesis and their therapeutic implications.

Yoo J, Kim G, Jeon Y, Lee S, Kwon S Cell Death Dis. 2024; 15(6):451.

PMID: 38926399 PMC: 11208531. DOI: 10.1038/s41419-024-06850-z.


The emerging roles of histone demethylases in cancers.

Tong D, Tang Y, Zhong P Cancer Metastasis Rev. 2024; 43(2):795-821.

PMID: 38227150 DOI: 10.1007/s10555-023-10160-9.


The Importance of M1-and M2-Polarized Macrophages in Glioma and as Potential Treatment Targets.

Ren J, Xu B, Ren J, Liu Z, Cai L, Zhang X Brain Sci. 2023; 13(9).

PMID: 37759870 PMC: 10526262. DOI: 10.3390/brainsci13091269.


Histone Demethylase KDM3 (JMJD1) in Transcriptional Regulation and Cancer Progression.

Fan L, Sudeep K, Qi J Adv Exp Med Biol. 2023; 1433:69-86.

PMID: 37751136 PMC: 11052651. DOI: 10.1007/978-3-031-38176-8_4.


References
1.
Dobin A, Davis C, Schlesinger F, Drenkow J, Zaleski C, Jha S . STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012; 29(1):15-21. PMC: 3530905. DOI: 10.1093/bioinformatics/bts635. View

2.
Chen L, Deshpande A, Banka D, Bernt K, Dias S, Buske C . Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l. Leukemia. 2012; 27(4):813-22. PMC: 3932800. DOI: 10.1038/leu.2012.327. View

3.
Brauchle M, Yao Z, Arora R, Thigale S, Clay I, Inverardi B . Protein complex interactor analysis and differential activity of KDM3 subfamily members towards H3K9 methylation. PLoS One. 2013; 8(4):e60549. PMC: 3623819. DOI: 10.1371/journal.pone.0060549. View

4.
Neff T, Armstrong S . Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood. 2013; 121(24):4847-53. PMC: 3682337. DOI: 10.1182/blood-2013-02-474833. View

5.
Miller P, Al-Shahrour F, Hartwell K, Chu L, Jaras M, Puram R . In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 2013; 24(1):45-58. PMC: 3746037. DOI: 10.1016/j.ccr.2013.05.004. View